2016 American Society of Hematology Annual Meeting *

December 3-6, 2016; San Diego, California
This program provides coverage of the 2016 ASH annual meeting with PowerPoint summaries and expert analysis of the most clinically relevant study results with downloadable highlights slidesets. Topics include lymphomas/CLL, leukemias, myeloma, and other hematologic malignancies.

Share

Program Content

Activities

Heme Malignancies San Diego 2016
Preview of ASH 2016: Top Expert-Selected Studies
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: December 01, 2016

Expires: November 30, 2017

Activities

Vadastuximab Talirine in AML
Addition of Vadastuximab Talirine to 7 + 3 Induction Therapy for Newly Diagnosed AML: Phase Ib Dose-Escalation Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 05, 2016

Expires: December 04, 2017

TOWER: Blinatumomab QoL
Phase III TOWER Substudy: Blinatumomab Shows Health-Related QoL Benefit vs Chemotherapy in R/R Ph- B-Precursor ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2016

Expires: December 05, 2017

INO + Mini-HCVD in ALL
Inotuzumab Ozogamicin Plus Reduced-Intensity Chemotherapy Active in Untreated Older Patients With ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2016

Expires: December 06, 2017

ABL001 in TKI-Resistant CML
Phase I ABL001X2101: Novel BCR-ABL1 Inhibitor ABL001 Safe With Promising Activity in TKI-Resistant Chronic-Phase CML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2016

Expires: December 06, 2017

SGN-CD33A + HMA in Untreated AML
Vadastuximab Talirine + Hypomethylating Agents Active and Well Tolerated in Untreated Older Patients With AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2016

Expires: December 07, 2017

Vorinostat in Untreated AML
Phase III SWOG S1203: Idarubicin + High-Dose Cytarabine ± Vorinostat vs Standard Therapy in Newly Diagnosed AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2016

Expires: December 07, 2017

ELIANA: CTL019 in R/R ALL
ELIANA: CTL019 Shows High CR Rate in Pediatric/Young Adult Patients With Relapsed/Refractory B-Cell ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2016

Expires: December 08, 2017

TKI Cessation in CML
Phase III EURO-SKI: Cessation of TKI Therapy Safe, Feasible for Pts Who Achieve Deep Molecular Response
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2016

Expires: December 08, 2017

Ponatinib + Hyper-CVAD in Ph+ ALL
Ponatinib Plus Hyper-CVAD Active as Frontline Therapy in Ph+ ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2016

Expires: December 11, 2017

Downloadable Slideset
Leukemias
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2016

Expires: December 19, 2017

Activities

MRD With Daratumumab in R/R MM
Daratumumab Combinations Increase MRD Negativity vs Rd or Vd Alone in Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 05, 2016

Expires: December 04, 2017

Selinexor + Dex in Ref MM
Phase II STORM Trial: Selinexor + Dexamethasone Is Active in Patients With Heavily Pretreated Refractory MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2016

Expires: December 05, 2017

Response-Based MM Induction
Phase III Myeloma XI: Response-Adapted Induction Improves Outcomes in Newly Diagnosed Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2016

Expires: December 05, 2017

Car/Pom/Dex in RR MM
Phase I/II Trial: Weekly Carfilzomib, Pomalidomide, and Dexamethasone in R/R Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2016

Expires: December 06, 2017

SC Daratumumab in MM (PAVO)
Phase Ib PAVO Study: Subcutaneous Daratumumab in Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2016

Expires: December 06, 2017

Venetoclax in R/R Myeloma
Venetoclax Monotherapy for Relapsed/Refractory MM: Phase I Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2016

Expires: December 06, 2017

Pembro + Pom/Dex in R/R MM
Phase II Study: Pembrolizumab Plus Pomalidomide and Dexamethasone Active in R/R Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2016

Expires: December 07, 2017

STaMINA: Post-ASCT Tx in MM
Phase III STaMINA Trial: Similar PFS With Single ASCT, Single ASCT Followed by RVD Consolidation, and Tandem ASCT in Frontline MM Treatment
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2016

Expires: December 08, 2017

IFM Phase II: KRd in MM
IFM Phase II Study: KRd Induction and Consolidation Before Len Maintenance Highly Effective in Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2016

Expires: December 08, 2017

Dara/Pom/Dex in RR MM
Daratumumab/Pom/Dex Salvage Beneficial in R/R MM Single Institution Retrospective Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2016

Expires: December 11, 2017

Downloadable Slideset
Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 27, 2016

Expires: December 26, 2017

Activities

Ibrutinib Discontinuation
Retrospective Analysis of Ibrutinib Discontinuation and Outcomes in CLL in Trial vs Real-World Settings
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 05, 2016

Expires: December 04, 2017

Brentuximab Vedotin for CTCL
ALCANZA: Brentuximab Vedotin vs Methotrexate or Bexarotene in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2016

Expires: December 05, 2017

REMARC: Lenalidomide Maintenance in DLBCL
REMARC: Lenalidomide vs Placebo as Maintenance Therapy in Patients With DLBCL Following R-CHOP Induction
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2016

Expires: December 05, 2017

LyMa Trial in MCL
Phase III LyMa Trial: Post-ASCT Rituximab Maintenance Increases Survival for Younger Patients With Mantle Cell Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2016

Expires: December 05, 2017

R-CHOP vs DA-EPOCH-R in DLBCL
CALGB/Alliance 50303: R-CHOP vs DA-EPOCH-R in Newly Diagnosed Diffuse Large B-Cell Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2016

Expires: December 06, 2017

Venetoclax in R/R CLL
Venetoclax in Patients With CLL Relapsed/Refractory to Ibrutinib or Idelalisib
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2016

Expires: December 07, 2017

CART in Refractory DLBCL
Phase II ZUMA-1: Interim Analysis of Anti-CD19 CAR T-Cell Therapy in Patients With Refractory Aggressive DLBCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2016

Expires: December 08, 2017

BR vs FCR Long-term Outcomes
CL110: Updated Analysis of First-line BR vs FCR in Fit Patients With Chronic Lymphocytic Leukemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2016

Expires: December 08, 2017

Rituximab + LEN in FL
Phase II SAKK 35/10 Trial: Rituximab Plus Lenalidomide Shows Durable Activity in Untreated Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2016

Expires: December 08, 2017

GALLIUM: Obinutuzumab in FL
GALLIUM: Obinutuzumab- vs Rituximab-Based Immunochemotherapy in Patients With Untreated Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2016

Expires: December 08, 2017

Phase II: Ibrutinib in MZL
Phase II PCYC-1121 Trial: Ibrutinib Monotherapy Active in R/R Marginal Zone Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2016

Expires: December 11, 2017

GP2013 in Follicular Lymphoma
ASSIST-FL: Rituximab Biosimilar GP2013 vs Rituximab in Treatment-Naive Patients With Advanced Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2016

Expires: December 11, 2017

Pembrolizumab in R/R cHL
KEYNOTE-087: Pembrolizumab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2016

Expires: December 11, 2017

Downloadable Slideset
Lymphomas and CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: January 05, 2017

Expires: January 04, 2018

Activities

Enasidenib in m<i>IDH2</i> MDS
Enasidenib Active, Well Tolerated in Small Cohort of MDS Patients With IDH2 Mutation
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2016

Expires: December 05, 2017

Low-Dose HMAs in LR MDS
Low-Dose Hypomethylating Agents Active, Safe in Low- and Intermediate-1–Risk MDS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2016

Expires: December 05, 2017

EPO Sensitivity in LR MDS
Lenalidomide + Epoetin alfa Restores Erythropoietin Sensitivity in Patients With Lower-Risk Myelodysplastic Syndromes
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2016

Expires: December 05, 2017

RUX + AZA in Myelofibrosis
Ruxolitinib + Azacitidine in Newly Diagnosed or R/R, Intermediate- or High-Risk Myelofibrosis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2016

Expires: December 06, 2017

Sotatercept in MPN-Associated Anemia
Sotatercept Active in Patients With Myeloproliferative Neoplasm–Associated Anemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2016

Expires: December 07, 2017

Downloadable Slideset
Myelodysplastic Syndrome and Myeloproliferative Neoplasms
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2016

Expires: December 18, 2017

MPD-RC 112: PegIFN α-2a vs HU in PV/ET
MPD-RC 112: Frontline Peginterferon α-2a vs Hydroxyurea in High-Risk Polycythemia Vera and Essential Thrombocythemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022
Ropeginterferon α-2b vs HU in PV
Phase III PROUD-PV: Ropeginterferon α-2b Noninferior to Hydroxyurea in Polycythemia Vera
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022
NIVO or IPI ± AZA in MDS
Nivolumab or Ipilimumab ± Azacitidine in Treatment-Naive or HMA-Failed Myelodysplastic Syndromes
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Faculty

cover img faculity

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

cover img faculity

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.